Targeting oxidative stress component in the therapeutics of epilepsy

Current Topics in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 994-1007

  Azam, Faizul ^a   Prasad, M V V ^b   Thangavel, Neelaveni ^b  

^a NIMS UNIVERSITY   (India)

^b CMR college of Pharmacy   (India)

Author keywords

Antioxidants; Free radicals; Neuroprotection; Oxidative stress

Indexed keywords

1 [4 (4 FLUOROPHENOXY)BENZYL]SEMICARBAZIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ALPHA TOCOPHEROL; ALPHA TOCOPHERYL LEVO ASCORBATE 2 O PHOSPHATE DIESTER; ANTICONVULSIVE AGENT; ASCORBIC ACID; BARBITURIC ACID DERIVATIVE; BUSPIRONE; DIAZEPAM; EPIGALLOCATECHIN; ETIRACETAM; FELBAMATE; HUPERZINE A; MELATONIN; PAN 811; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYTOIN; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; RILUZOLE; ROSIGLITAZONE; SEMICARBAZIDE; THIOCTIC ACID; TIAGABINE; TOPIRAMATE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; YKP 3089; ZONISAMIDE;

ADD ON THERAPY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; BIPOLAR DISORDER; BRAIN DEGENERATION; BRAIN INFARCTION; BRAIN ISCHEMIA; COGNITIVE DEFECT; ENZYME ACTIVITY; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; EPILEPTOGENESIS; FOCAL EPILEPSY; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; ISCHEMIA; KETOGENIC DIET; LIPID PEROXIDATION; MEMORY DISORDER; MICROGLIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NERVE CELL MEMBRANE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; REVIEW; SEIZURE;

EID: 84860481514     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800229224     Document Type: Review

References (220)

1. Papandreou, D.; Pavlou, E.; Kalimeri, E.; Mavromichalis, I. The ketogenic diet in children with epilepsy. Br. J. Nutr., 2006, 95, 5-13.
2. Gummit, R.J. The Epilepsy Handbook, The Practical Management of Seizures, Raven Press: New York, 1983.
3. Mishra, M.; Singh, R.; Sharma, D. Antiepileptic action of exogenous dehydroepiandrosterone in iron-induced epilepsy in rat brain. Epilepsy Behav., 2010, 19, 264-271.
4. Obeid, M.; Frank, J.; Medina, M.; Finckbone, V.; Bliss, R.; Bista, B.; Majmudar, S.; Hurst, D.; Strahlendorf, H.; Strahlendorf, J. Neuroprotective effects of leptin following kainic acid-induced status epilepticus. Epilepsy Behav., 2010, 19(3), 278-283.
5. Schauwecker, P.E. Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain. Exp. Neurol., 2010, 224, 207-218.
6. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine, 2nd ed.; Clarendon Press: Oxford. 1989.
7. Reiter, R.J. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J., 1995, 9, 526-533.
8. Wilson, J.X. Antioxidant defense of the brain: a role for astrocytes. Can. J. Physiol. Pharmacol., 1997, 75, 1149-1163.
9. Jenner, P.; Olanow, C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 1996, 47(Suppl 3), S161-S170.
10. Simonian, N.A.; Coyle, J.T. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol., 1996, 36, 83-106.
11. Sayre, L.M.; Perry, G.; Smith, M.A. Oxidative Stress and Neurotoxicity. Chem. Res. Toxicol., 2008, 21(1), 172-188.
12. Azam, F. In: Handbook of Free Radicals: Formation, Types and Effects. Kozyrev, D.; Slutsky, V.; Ed.; Nova Science Publishers: New York, 2010; pp. 57-97.
13. Brown, G.C. Nitric oxide and neuronal death. Nitric Oxide, 2010, 23(3), 153-65.
14. Esposito, E.; Cuzzocrea, S. New therapeutic strategy for Parkinson's and Alzheimer's disease. Curr. Med. Chem., 2010, 17(25), 2764-2774.
15. Jomova, K.; Vondrakova, D.; Lawson, M.; Valko, M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell Biochem., 2010, 345(1-2), 91-104.
16. Higgins, G.C.; Beart, P.M.; Shin, Y.S.; Chen, M.J.; Cheung, N.S.; Nagley, P. Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J. Alzheimers Dis., 2010, 20(Suppl 2), S453-S473.
17. Smith, D.G.; Cappai, R.; Barnham, K.J. The redox chemistry of the Alzheimer's disease amyloid β peptide. Biochim. Biophys. Acta, 2007, 1768, 1976-1990.
18. Evans, P.H. Free radicals in brain metabolism and pathology. Br. Med. Bull., 1993, 49, 577-587.
19. Liu, J.; Wang, A.; Li, L.; Huang, Y.; Xue, P.; Hao, A. Oxidative stress mediates hippocampal neuron death in rats after lithiumpilocarpine-induced status epilepticus. Seizure, 2010, 19(3), 165-172.
20. Gonsette, R.E. Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. J. Neurol. Sci., 2008, 274, 48-53.
21. Emerit, J.; Edeas, M.; Bricaire, F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother., 2004, 58(1), 39-46.
22. Zatta, P. Metal ions and neurodegenerative disorders, World Scientific Publishing Co. Pte. Ltd: Singapore, 2003.
23. Ercegovac, M.; Jovic, N.; Simic, T.; Beslac-Bumbasirevic, L.; Sokic, D.; Djukic, T.; Savic-Radojevic, A.; Matic, M.; Mimic-Oka, J.; Pljesa-Ercegovac, M. Byproducts of protein, lipid and DNA oxidative damage and antioxidant enzyme activities in seizure. Seizure, 2010, 19, 205-210.
24. Bruce, A.J.; Baudry, M. Oxygen free radicals in rat limbic structures after kainite-induced seizures. Free Radic. Biol. Med., 1995, 18, 993-1002.
25. Singh, R.; Pathak, D.N. Lipid peroxidation and glutathione peroxidase, glutathione reductase, superoxide dismutase, catalase, and glucose-6-phosphate dehydrogenase activities in FeCl3-induced epileptogenic foci in the rat brain. Epilepsia, 1990, 31, 15-26.
26. McCormick, D.A.; Contreras, D. On the cellular and network bases of epileptic seizures. Annu. Rev. Physiol., 2001, 63, 815-846.
27. Chuang, Y.-C.; Mitochondrial Dysfunction and Oxidative Stress in Seizure-Induced Neuronal Cell Death. Acta Neurol. Taiwan, 2010, 19, 3-15.
28. Fujikawa, D.G. Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav., 2005, 7(Suppl 3), S3-S11.
29. Meldrum, B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology, 1994, 44, 14-23.
30. Ferrer, I.; Martin, F.; Reiriz, J.; Perez-Navarro, E.; Alberch, J.; Macaya, A.; Planas, A.M. Both apoptosis and necrosis occur following intrastriatal administration of excitotoxins. Acta Neuropathol., 1995, 90, 504-510.
31. Leite, J.P.; Bortolotto, Z.A.; Cavalheiro, E.A. Spontaneous recurrent seizures in rats: an experimental model of partial epilepsy. Neurosci. Biobehav. Rev., 1990, 14, 511-517.
32. Agostinho, P.; Duarte, C.B.; Oliveira, C.R. Activity of ionotropic glutamate receptors in retinal cells: Effect of ascorbate/Fe(2+)-induced oxidative stress. J. Neurochem., 1996, 67, 1153-1163.
33. Cendes, F. Progressive hippocampal and extrahippocampal atrophy in drug resistant epilepsy. Curr. Opin. Neurol., 2005, 18, 173-177.
34. Sutula, T.P.; Hagen, J.; Pitkanen, A. Do epileptic seizures damage the brain? Curr. Opin. Neurol., 2003, 16, 189-195.
35. DeGiorgio, C.M.; Tomiyasu, U.; Gott, P.S.; Treiman, D.M. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia, 1992, 33, 23-27.
36. Duncan, J.S. Seizure-induced neuronal injury: human data. Neurol. 2002, 59, S15-S20.
37. Haut, S.R.; Veliskova, J.; Moshe, S.L. Susceptibility of immature and adult brains to seizure effects. Lancet Neurol., 2004, 3, 608-617.
38. Wasterlain, C.G.; Fujikawa, D.G.; Penix, L.; Sankar, R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia, 1993, 34(Suppl 1), S37-S53.
39. Patel, M. Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic. Biol. Med., 2004, 37, 1951-1962.
40. Azam, F.; Alkskas, I.A.; Khokra, S.L.; Prakash, O. Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants. Eur. J. Med. Chem., 2009, 44, 203-211.
41. Azam, F.; El-gnidi, B.A.; Alkskas, I.A. Combating oxidative stress in epilepsy: Design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides. Eur. J. Med. Chem., 2010, 45(7), 2817-2826.
42. Abdallah, D.M. Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res., 2010, 1351, 246-253.
43. Yu, X.; Shao, X.G.; Sun, H.; Li, Y.N.; Yang, J.; Deng, Y.C.; Huang, Y.G. Activation of cerebral peroxisome proliferatoractivated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res., 2008, 1200, 146-158.
44. Halliwell, B. The wanderings of a free radical. Free Radic. Biol. Med., 2009, 46, 531-542.
45. Kamat, C.D.; Gadal, S.; Mhatre, M.; Williamson, K.S.; Pye, Q.N.; Hensley, K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J. Alzheimers Dis., 2008, 15(3), 473-493.
46. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39(1), 44-84.
47. Azam, F.; El-gnidi, B.A.; Alkskas, I.A. Ahmed, M.A. Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]-pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice. J. Enzyme Inhib. Med. Chem., 2010, 25(6), 818-826.
48. Kaur, C.; Ling, E.A. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr. Med. Chem., 2008, 15(29), 3068-3080.
49. Azam, F. Synthesis of some urea and thiourea derivatives of naphtha[1,2-d]thiazol-2-amine as anti-Parkinsonian agents that cause neuroprotection against haloperidol-induced oxidative stress in mice. Med. Chem. Res., 2009, 18, 287-308.
50. Azam, F.; Alkskas, I.A.; Ahmed, M.A. Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice. Eur. J. Med. Chem., 2009, 44(10), 3889-3897.
51. Azam, F.; Barodia, S.K.; Anwer, T.; Alam, M.M. Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. J. Enzyme Inhib. Med. Chem., 2009, 24(3), 808-817.
52. Kiaei, M.; Kipiani, K.; Chen, J.; Calingasan, N.Y.; Beal, M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 2005, 191, 331-336.
53. Roses, A.D.; Saunders, A.M.; Huang, Y.; Strum, J.; Weisgraber, K.H.; Mahley, R.W. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J., 2007, 7, 10-28.
54. Okada, K.; Yamashita, U.; Tsuji, S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res., 2006, 1102, 175-178.
55. Maurois, P.; Rocchi, S.; Pages, N.; Bac, P.; Stables, J.P.; Gressens, P.; Vamecq, J. The PPARgamma agonist FMOC-L-leucine protects both mature and immature brain. Biomed. Pharmacother., 2008, 62, 259-263.
56. Sun, H.; Huang, Y.; Yu, X.; Li, Y.; Yang, J.; Li, R.; Deng, Y.; Zhao, G. Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. Int. J. Dev. Neurosci., 2008, 26, 505-515.
57. Kim, S.R.; Lee, K.S.; Park, H.S.; Park, S.J.; Min, K.H.; Jin, S.M.; Lee, Y.C. Involvement of IL-10 in peroxisome proliferatoractivated receptor gamma-mediated anti-inflammatory response in asthma. Mol. Pharmacol., 2005, 68, 1568-1575.
58. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; Palmer, C.N.; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58, 726-741.
59. Krag, M.B.; Rasmussen, L.M.; Hansen, T.K.; Frystyk, J Flyvbjerg, A.; Moller, N.; Jorgensen, J.O. Peroxisome proliferatoractivated receptor gamma agonism reduces the insulin-stimulated increase in circulating interleukin-6 in growth hormone (GH) replaced GH-deficient adults. Clin. Endocrinol., 2009, 71, 363-368.
60. Girnun, G.D.; Domann, F.E.; Moore, S.A.; Robbins, M.E. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol., 2002, 16, 2793-2801.
61. Hwang, J.; Kleinhenz, D.J.; Lassegue, B.; Griendling, K.K.; Dikalov, S.; Hart, C.M. Peroxisome proliferator-activated receptorgamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol., 2005, 288, C899-C905.
62. Ding, G.; Fu, M.; Qin, Q.; Lewis, W.; Kim, H.W.; Fukai, T.; Bacanamwo, M.; Chen, Y.E.; Schneider, M.D.; Mangelsdorf, D.J.; Evans, R.M.; Yang, Q. Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc. Res., 2007, 76, 269-279.
63. Farooqui, A.A.; Ong, W.Y.; Horrocks, L.A.; Farooqui, T. Brain cytosolic phospholipase A2: Localization, role, and involvement in neurological diseases. Neuroscientist, 2000, 6, 169-180.
64. Farooqui, A.A.; Ong, W.Y.; Horrocks, L.A. Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders. Pharmacol. Rev., 2006, 58, 591-620.
65. Visioli, F.; de Turco, E.B.R.; Kreisman, N.R.; Bazan, N.G. Membrane lipid degradation is related to interictal cortical activity in a series of seizures. Metab. Brain Dis., 1994, 9, 161-170.
66. Kajiwara, K.; Nagawawa, H.; Shimizu-Nishikawa, S.; Ookuri, T.; Kimura, M.; Sugaya, E. Molecular characterization of seizurerelated genes isolated by differential screening. Biochem. Biophys. Res. Commun., 1996, 219, 795-799.
67. Yegin, A.; Akbas, S.H.; Ozben, T.; Korgun, D.K. Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model. Acta Neurol. Scand., 2002, 106, 258-262.
68. Cai, S.X.; Lan, N.C.; Hong-bae, Soo. Substituted semicarbazides and the use there of. US Patent 6281211, 2001.
69. Nardi, A.; Demnitz, J.; Grunnet, M.; Christophersen, P.; Jones, D.S.; Nielsen, E.O.; Strobaek, D.; Madsen, L.S. Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators. US Patent Appl. 20100137327, 2010.
70. + channel modulators as neuroprotective agents. Life Sci., 2010, 86, 775-780.
71. Chen, R.W.; Yao, C.; Lu, X.C.; Jiang, Z.G.; Whipple, R.; Liao, Z.; Ghanbari, H.A.; Almassian, B.; Tortella, F.C.; Dave, J.R. PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression. Neurosci., 2005, 135(1), 191-201.
72. Chen, R.W.; Lu, X.C.; Yao, C.; Liao, Z.; Jiang, Z.G.; Wei, H.; Ghanbari, H.A.; Tortella, F.C.; Dave, J.R. PAN-811 provides neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK. Neurosci. Lett., 2007, 422(1), 64-67.
73. Tam, T.F.; Leung-Toung, R.; Li, W.; Wang, Y.; Karimian, K.; Spino, M. Curr. Med. Chem., 2003, 10, 983-995.
74. Jiang, Z.G.; Lu, X.-C.M.; Nelson, V.; Yang, X.; Pan, W.; Chen, R.-W.; Lebowitz, M.S.; Almassian, B.; Tortella, F.C.; Brady, R.O.; Ghanbari, H.A. A multifunctional cytoprotective agent that reduces neurodegeneration after ischemia. PNAS, 2006, 103(5) 1581-1586.
75. Nelson, V.M.; Dancik, C.M.; Pan, W.; Jiang, Z.G.; Lebowitz, M.S.; Ghanbari, H.A. PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J. Alzheimers Dis., 2009, 17(3), 611-619.
76. Ohlsen, R.I.; Pilowsky, L.S. The place of partial agonism in psychiatry: recent developments, J. Psychopharmacol., 2005, 19(4), 408-413.
77. Lucki, I.; Singh, A.; Kreiss, D.S. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci. Biobehav. Rev., 1994, 18, 85-95.
78. de Freitas, R.L.; Santos, I.M.; de Souza, G.F.; Tome, A.R.; Saldanha, G.B.; de Freitas, R.M. Oxidative stress in rat hippocampus caused by pilocarpine-induced seizures is reversed by buspirone. Brain Res. Bull., 2010, 81(4-5), 505-509.
79. Lauterbach, E.C.; Victoroff, J.; Coburn, K.L.; Shillcutt, S.D.; Doonan, S.M.; Mendez, M.F. Psychopharmacological Neuroprotection in Neurodegenerative Disease: Assessing the Preclinical Data. J. Neuropsychiat. Clin. Neurosci., 2010, 22, 8-18.
80. McConnell, H.; Duncan, D. In: Psychiatric Comorbidity in Epilepsy: Basic Mechanisms, Diagnosis, and Treatment; McConnell, H.; Snyder, P.J. Ed.; American Psychiatric Press: Washington, DC, 1998; pp. 245-362.
81. Ved, H.S.; Koenig, M.L.; Dave, J.R.; Doctor, B.P. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport, 1997, 8, 963-968.
82. Zangara, A. The psychopharmacology of huperzine A: an alka- loid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav., 2003, 75, 675-686.
83. Bialer, M.; Johannessen, S.I.; Levy, R.H.; Perucca, E.; Tomson, T.; White, H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res., 2010, 92(2-3), 89-124.
84. White, H.S.; Schachter, S.; Lee, D.; Xiaoshen, J.; Eisenberg, D. Anticonvulsant activity of Huperzine A, an alkaloid extract of Chinese club moss (Huperzia serrata). Epilepsia, 2005, 46(Suppl 8), 220.
85. Zhou, J.; Tang, T. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett., 2002, 526, 21-25.
86. Zhou, J.; Zhang, H.Y.; Tang, X.C. Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett., 2001, 313, 137-140.
87. Ye, J.W.; Cai, J.X.; Wang, L.M.; Tang, X.C. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J. Pharmacol. Exp. Ther., 1999, 288, 814-819.
88. Bialer, M.; Johannessen, S.I.; Levy, R.H.; Perucca, E.; Tomson, T.; White, H.S. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res., 2009, 83(1), 1-43.
89. Turunen, M.; Olsson, J.; Dallner, G. Metabolism and function of coenzyme Q. Biochim. Biophys. Acta., 2004, 1660, 171-199.
90. + on coenzyme Q content. Life Sci., 2008, 83, 92-95.
91. Haas, R.H. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion, 2007, 7(Suppl), S136-S145.
92. Cordero, M.D.; Moreno-Fernandez, A.M.; Gomez-Skarmeta, J.L.; de Miguel, M.; Garrido-Maraver, J.; Oropesa-Avila, M.; Rodriguez-Hernandez, A.; Navas, P.; Sanchez-Alcazar, J.A. Coenzyme Q10 and alpha-tocopherol protect against amitriptyline toxicity. Toxicol. Appl. Pharmacol., 2009, 235(3), 329-337.
93. Morre, D.M.; Morre, D.J.; Rehmus, W.; Kern, D. Supplementation with CoQ10 lowers age-related (ar) NOX levels in healthy subjects. Biofactors, 2008, 32(1-4), 221-230.
94. Yoshida, Y.; Hayakawa, M.; Habuchi, Y.; Niki, E. Evaluation of the dietary effects of coenzyme Q in vivo by the oxidative stress marker, hydrocyoctadecadienoic and its steroisomer ratio. Biochim. Biophys. Acta, 2006, 1760, 1558-1568.
95. Cooper, J.M.; Korlipara, L.V.; Hart, P.E.; Bradley, J.L.; Schapira, A.H. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol., 2008, 15(12), 1371-1379.
96. Abdin, A.A.; Hamouda, H.E. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism. Neuropharmacology, 2008, 55(8), 1340-1346.
97. Echtay, K.S.; Winkler, E.; Klingenberg, M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature, 2000, 408, 609-613.
98. Mattiasson, G.; Shamloo, M.; Gido, G.; Mathi, K.; Tomasevic, G.; Yi, S.; Warden, C.H.; Castilho, R.F.; Melcher, T.; Gonzalez-Zulueta, M.; Nikolich, K.; Wieloch, T. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat. Med., 2003 9(8), 1062-1068.
99. Alleva, R.; Tomasetti, M.; Andera, L.; Gellert, N.; Borghi, B.; Weber, C.; Murphy, M.P.; Neuzil, J. Coenzyme Q10 blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett., 2001, 503, 46-50.
100. Somayajulu, M.; McCarthy, S.; Hung, M.; Sikorska, M.; Borowy-Borowski, H.; Pandey, S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q10. Neurobiol. Dis., 2005, 18, 618-627.
101. 10. Neurochem. Res., 2006, 31, 303-311.
102. Young, A.J.; Johnson, S.; Steffens, D.C.; Doraiswamy, P.M. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr., 2007, 12(1), 62-68.
103. Santos, I.M.; de Freitas, R.L.; da Silva, E.P.; Feitosa, C.M.; Saldanha, G.B.; Souza, G.F.; Tome, A.R.; Feng, D.; de Freitas, R.M. Effects of ubiquinone on hydroperoxide concentration and antioxidant enzymatic activities in the rat hippocampus during pilocarpine-induced seizures. Brain Res., 2010, 1315, 33-40.
104. Tsai, H.L.; Chang, C.N.; Chang, S.J. The effects of pilocarpineinduced status epilepticus on oxidative stress/damage in developing animals. Brain Dev., 2010, 32, 25-31.
105. Freitas, R.M. Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neurosci. Lett., 2009, 462, 225-229.
106. Smith, A.R.; Shenvi, S.V.; Widlansky, M.; Suh, J.H.; Hagen, T.M. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem., 2004, 11, 1135-1146.
107. Goraca, A.; Asłanowicz-Antkowiak, K. Prophylaxis with alphalipoic acid against lipopolysaccharide-induced brain injury in rats. Arch. Immunol. Ther. Exp. (Warsz), 2009, 57(2), 141-146.
108. Toklu, H.Z.; Hakan, T.; Biber, N.; Solakoglu, S.; Ogunc, A.V.; Sener, G. The protective effect of alpha lipoic acid against traumatic brain injury in rats. Free Radic. Res., 2009, 25, 1-10.
109. Fujita, H.; Shiosaka, M.; Ogino, T.; Okimura, Y.; Utsumi, T.; Sato, E.F.; Akagi, R.; Inoue, M.; Utsumi, K.; Sasaki, J. α-Lipoic acid suppresses 6-hydroxydopamine-induced ROS generation and apoptosis through the stimulation of glutathione synthesis but not by the expression of heme oxygenase-1. Brain Res., 2008, 1206, 1-12.
110. Freitas, R.M. The evaluation of effects of lipoic acid on the lipid peroxidation, nitrite formation and antioxidant enzymes in the hippocampus of rats after pilocarpine-induced seizures. Neurosci. Lett., 2009, 455(2), 140-144.
111. Byun, C.H.; Koh, J.M.; Kim, D.K.; Park, S.I.; Lee, K.U.; Kim, G.S. Alpha-lipoic acid inhibits TNF-alpha-induced apoptosis in human bone marrow stromal cells. J. Bone Miner. Res., 2005, 20, 1125-1135.
112. Vincent, A.M.; McLean, L.L.; Backus, C.; Feldman, E.L. Shortterm hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J., 2005, 19(6), 638-640.
113. Militao, G.C.; Ferreira, P.M.; de Freitas, R.M. Effects of lipoic acid on oxidative stress in rat striatum after pilocarpine-induced seizures. Neurochem. Int., 2010, 56(1), 16-20.
114. +-ATPase activity in rat brain Pharmacology. Biochem. Behav., 2010, 95, 88-91.
115. dos Santos, P.S.; Feitosa, C.M.; Saldanha, G.B.; Tome, A.D.R.; Feng, D.; de Freitas, R.M. Lipoic acid inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after pilocarpine-induced seizures. Pharmacol. Biochem. Behav., 2011, 97, 531-536.
116. Maczurek, A.; Hager, J.; Kenklies, M.; Sharman, M.; Martins, R.; Engel, J.; Carlson, D.A.; Munch, G. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv. Drug Deliv. Rev., 2008, 60, 1463-1470.
117. Kudin, A.P.; Bimpong-Buta, N.Y.; Vielhaber, S.; Elger, C.E.; Kunz, W.S. Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem., 2004, 279, 4127-4135.
118. Bellissimo, M.I.; Amado, D.; Abdalla, D.S.P.; Ferreira, E.; Cavalheiro, E.A.; Naffah-Mazzacoratti, M.G. Superoxide dismutase, glutathione peroxidase activities and the hydroperoxide concentration are modified in the hippocampus of epileptic rats. Epilep. Res., 2001, 46, 121-128.
119. +-ATPase and acetylcholinesterase activities in rat hippocampus after pilocarpine-induced seizures? Arq. Neuropsiquiatr., 2010, 68, 586-591.
120. Hardeland, R.; Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin-A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol., 2011, 93(3), 350-384.
121. Pandi-Perumal, S.R.; Trakht, I.; Srinivasan, V.; Spence, D.W.; Maestroni, J.G.M.; Zisapel, N.; Cardinali, D.P. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog. Neurobiol., 2008, 85, 335-353.
122. Berra, B.; Rizzo, A.M. Melatonin: circadian rhythm regulator, chronobiotic, antioxidant and beyond. Clin. Dermatol., 2009, 27, 202-209.
123. Fischer, T.W.; Slominski, A.; Zmijewski, M.A.; Reiter, R.J.; Paus, R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp. Dermatol., 2008, 17, 713-730.
124. Korkmaz, A.; Reiter, R.J.; Topal, T.; Manchester, L.C.; Oter, S.; Tan, D.X. Melatonin: An established antioxidant worthy of use in clinical trials. Mol. Med., 2009, 15(1-2), 43-50.
125. Reiter, R.J.; Tan, D.X.; Jou, M.J.; Korkmaz, A.; Manchester, L.C.; Paredes, S.D. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro. Endocrinol. Lett., 2008, 29(4), 391-398.
126. Maharaj, D.S.; Maharaj, H.; Daya, S.; Glass, B.D. Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity. J. Neurochem., 2006, 96, 78-81.
127. Catala, A. The ability of melatonin to counteract lipid peroxidation in biological membranes. Curr. Mol. Med., 2007, 7, 638-649.
128. Rodriguez, C.; Mayo, J.C.; Sainz, R.M.; Antolin, I.; Herrera, F.; Martin, V.; Reiter, R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res., 2004, 36(1), 1-9.
129. Hardeland, R.; Pandi-Perumal, S.R.; Cardinali, D.P. Molecules in focus. Int. J. Biochem. Cell Biol., 2006, 38, 313-316.
130. Winiarska, K.; Fraczyk, T.; Malinska, D.; Drozak, J.; Bryla, J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J. Pineal Res., 2006, 40, 168-176.
131. Mevissen, M.; Ebert, U. Anticonvulsant effects of melatonin in amygdala kindled rats. Neurosci. Lett., 1998, 257, 6-13.
132. Srivastava, A.K.; Gupta, S.K.; Jain, S.; Gupta, Y.K. Effect of melatonin and phenytoin on an intracortical ferric chloride model of posttraumatic seizures in rats. Meth. Find. Exp. Clin. Pharmacol., 2002, 24, 145-149.
133. Reiter, R.J.; Tan, D.X.; Poeggler, B.; Menedez-Palaez, A.; Chen, L.D.; Saarela, S. Melatonin as a free radical scavenger. Implications for ageing and age related diseases. Ann. NY. Acad. Sci., 1994, 719, 1-19.
134. Mohanan, P.V.; Yamamoto, H.A. Preventive effect of melatonin against brain mitochondria DNA damage, lipid peroxidation and seizures induced by kainic acid. Toxicol. Lett., 2002, 129(1-2), 99-105.
135. Dabbeni-Sala, F.; Floreani, M.; Franceschini, D.; Skaper, S.D.; Giusti, P. Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester. FASEB J., 2001, 15(10), 1786-1788.
136. Molina-Carballo, A.; Munoz-Hoyos, A.; Reiter, R.J.; Sanchez-Forte, M.; Moreno-Madrid, F.; Rufo-Campos, M.; Molina-Font, J.A.; Acuna-Castroviejo, D. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J. Pineal Res., 1997, 23(2), 97-105.
137. Bikjdaouene, L.; Escames, G.; Leon, J.; Ferrer, J.M.; Khaldy, H.; Vives, F.; Acuna-Castroviejo, D. Changes in brain amino acids and nitric oxide after melatonin administration in rats with pentylenetetrazole-induced seizures. J. Pineal Res., 2003, 35(1), 54-60.
138. Akbulut, K.G.; Gonul, B.; Akbulut, H. Exogenous melatonin decreases age-induced lipid peroxidation in the brain. Brain Res., 2008, 1238, 31-35.
139. Kabuto, H.; Yokoi, I.; Ogawa, N. Melatonin inhibits iron-induced epileptic discharges in rats by suppressing peroxidation. Epilepsia, 1998, 39, 237-243.
140. Maharaj, D.S.; Glass, B.D.; Daya, S. Melatonin: New Places in Therapy. Biosci. Rep., 2007, 27, 299-320.
141. Gupta, M.; Gupta, Y.K.; Agarwal, S.; Aneja, S.; Kohli, K. A randomized, double-blind, placebo controlled trial of melatonin addon therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br. J. Clin. Pharmacol., 2004, 58, 542-547.
142. Peled, N.; Shorer, Z.; Peled, E.; Pillar, G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia, 2001, 42, 1208-1210.
143. Traber, M.G.; Atkinson, J. Vitamin E, antioxidant and nothing more. Free Radic. Biol. Med., 2007, 43, 4-15.
144. Cyrus, T.; Pratico, D. Vitamin E and Atherosclerosis. In: The encyclopedia of Vitamin; Preedy, E.V.R.; Watson, R.R. Eds.; CABI Publishing, Wallingford, UK, 2006; pp. 623-632.
145. Brigelius-Flohe, R. Vitamin E: the shrew waiting to be tamed. Free Radic. Biol. Med., 2009, 46(5), 543-554.
146. 31P-NMR using a Langendorff perfusion technique. J. Mol. Cell Cardiol., 1993, 25, 1067-1074.
147. Cao, L.; Chen, R.; Xu, J.; Lin, Y.; Wang, R.; Chi, Z. Vitamin E inhibits activated chaperone-mediated autophagy in rats with status epilepticus. Neuroscience, 2009, 161(1), 73-77.
148. Ayyildiz, M.; Yildirim, M.; Agar, E. The effects of vitamin E on penicillin-induced epileptiform activity in rats. Exp. Brain Res., 2006, 174(1), 109-113.
149. Ribeiro, M.C.P.; de Avila, D.S.; Schneider, C.Y.M.; Hermes, F.S.; Furian, A.F.; Oliveira, M.S.; Rubin, M.A.; Lehmann, M.; Kreiglstein, J.; Mello, C.F. α-Tocopherol protects against pentylenetetrazol-and methylmalonate-induced convulsions. Epilepsy Res., 2005, 66, 185-194.
150. Kryzhanovskii, G.N.; Nikushkin, E.V.; Braslavskii, V.E.; Glebov, R.N. Lipoperoxidation in the hyperactive focus of rat cerebral cortex. Biull. Eksp. Biol. Med., 1980, 89, 14-16.
151. Kovacs, R.; Schucmann, S.; Gabriel, S.; Kann, O.; Kardos, J.; Heinemnn, U. Free radical-mediated cell damage after experimental status epilepticus in hippocampal slice cultures. J. Neurophysiol., 2002, 88, 2909-2918.
152. Rauca, C.; Wiswedel, I.; Zerbe, R.; Keilho, V.G.; Krug, M. The role of superoxide dismutase and α-tocopherol in the development of seizures and kindling induced by pentylenetetrazol-infuence of the radical scavenger α-phenyl-N-tert-buthyl nitrone. Brain Res., 2004, 109, 203-212.
153. Ayyildiz, M.; Yildirim, M.; Agar, E. The involvement of nitric oxide in the anticonvulsant effects of alpha-tocopherol on penicillin-induced epileptiform activity in rats. Epilepsy Res., 2007, 73, 166-172.
154. Yamamoto, N.; Kabuto, H.; Matsumoto, S.; Ogawa, N.; Yokoi, I. α-Tocopheryl-L-ascorbate-2-O-phosphate diester, a hydroxyl radical scavenger, prevents the occurrence of epileptic foci in a rat model of post-traumatic epilepsy. Pathophysiology, 2002, 8, 205-214.
155. Tome, A.D.R.; Ferreira, P.M.P.; Freitas, R.M.D. Inhibitory action of antioxidants (ascorbic acid or α-tocopherol) on seizures and brain damage induced by pilocarpine in rats. Arq. Neuropsiquiatr., 2010, 68, 355-361.
156. Ricciarelli, R.; Argellati, F.; Pronzato, M.A.; Domenicotti, C. Vitamin E and neurodegenerative diseases. Mol. Aspects Med., 2007, 28, 591-606.
157. Tamai, H.; Wakamiya, E.; Mino, M.; Iwakoshi, M. Alphatocopherol and fatty acid levels in red blood cells in patients treated with antiepileptic drugs. J. Nutr. Sci. Vitaminol. (Tokyo), 1988, 34, 627-631.
158. Ogunmekan, A.O. Vitamin E deficiency and seizures in animals and man. Can. J. Neurol. Sci., 1979, 6, 43-45.
159. Barros, D.O.; Xavier, S.M.; Barbosa, C.O.; Silva, R.F.; Maia, F.D.; Oliveira, A.A.; Freitas, R.M.; Takahashi, R.N. Effects of the vitamin E in catalase activities in hippocampus after status epilepticus induced by pilocarpine in Wistar rats. Neurosci. Lett., 2007, 420, 76-79.
160. Ogunmekan, A.O.; Hwang, P.A. A randomized, double blind, placebo-controlled, clinical trial of d-alpha-tocopheryl acetate (vitamin E), as add-on therapy, for epilepsy in children. Epilepsia, 1989, 30, 84-89.
161. Sullivan, C.; Capaldi, N.; Mack, G.; Buchanan, N. Seizures and natural vitamin E. Med. J. Aust., 1990, 152, 613-614.
162. Raju, G.B.; Behari, M.; Prasad, K.; Ahuja, G.K. Randomized, double-blind, placebo-controlled, clinical trial of D-alphatocopherol (vitamin E) as add-on therapy in uncontrolled epilepsy. Epilepsia, 1994, 35, 368-372.
163. Xavier, S.M.; Barbosa, C.O.; Barros, D.O.; Silva, R.F.; Oliveira, A.A.; Freitas, R.M. Vitamin C antioxidant effects in hippocampus of adult Wistar rats after seizures and status epilepticus induced by pilocarpine. Neurosci. Lett., 2007, 420(1), 76-79.
164. Santos, L.F.; Freitas, R.L.; Xavier, S.M.; Saldanha, G.B.; Freitas, R.M. Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures. Pharmacol. Biochem. Behav., 2008, 89(1), 1-5.
165. Jain, K.K. The Handbook of Neuroprotection, Humana Press: New York, NY 10013, USA, 2011.
166. Jackson, T.S.; Xu, A.M.; Vita, J.A.; Keaney, J.F. Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ. Res., 1998, 83, 916-922.
167. Niki, E.; Noguchi, N.; Tsuchihashi, H.; Gotoh, N. Interaction among vitamin C, vitamin E, and β-carotene. Am. J. Clin. Nutr., 1995, 62(Suppl.), 1322S-1326S.
168. May, J.M.; Qu, Z.-C.; Mendiratta, S. Protection and recycling of α-tocopherol in human erythrocytes by intracellular ascorbic acid. Arch. Biochem. Biophys., 1998, 349, 281-289.
169. Ayyildiz, M.; Coskun, S.; Yildirim, M.; Agar, E. The effects of ascorbic acid on penicillin-induced epileptiform activity in rats. Epilepsia, 2007, 48(7), 1388-1395.
170. Mori, A.; Hiramatsu, M.; Yokoi, I.; Edamatsu, R. Biochemical pathogenesis of post-traumatic epilepsy. Pavlov J. Biol. Sci., 1990, 25, 54-62.
171. Fighera, M.R.; Queiroz, C.M.; Stracke, M.P.; Nin Brauer, M.C.; Gonzalez-Rodriguez, L.L.; Frussa-Filho, R.; Wajner, M.; de Mello, C.F. Ascorbic acid and α-tocopherol attenuate methylmalonic acid induced convulsions. Neuroreport, 1999, 10, 2039-2043.
172. Oliveira, M.S.; Furian, A.F.; Royes, L.F.F.; Fighera, M.R.; De Carvalho, J.; Fiorenza, N.G.; Mello, C.F. Ascorbate modulates pentylenetetrazol-induced convulsions biphasically. Neurosci., 2004, 128, 721-728.
173. Seregi, A.; Schaefer, A.; Komlos, M. Protective role of brain ascorbic acid content against lipid peroxidation. Experientia, 1978, 34, 1056-1057.
174. Kovachich, G.B.; Mishra, O.P. The effect of ascorbic acid on malonaldehyde formation, K+, Na+ andwater content of brain slices. Exp. Brain Res., 1983, 50, 62-68.
175. Sato, K.; Saito, H.; Katsuki, H. Synergism of tocopherol and ascorbate on the survival of cultured brain neurones. Neuroreport, 1993, 4, 1179-1182.
176. Bano, S.; Parihar, M.S. Reduction of lipid peroxidation in different brain regions by a combination of α-tocopherol and ascorbic acid. J. Neural Transm., 1997, 104, 1277-1286.
177. Harrison, F.E.; May, J.M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med., 2009, 46, 719-730.
178. Fumagalli, E.; Funicello, M.; Rauen, T.; Gobbi, M.; Mennini, T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur. J. Pharmacol., 2008, 578, 171-176.
179. Bough, K.J.; Rho, J.M. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia, 2007, 48, 43-58.
180. Gaby, A.R. Natural Approaches to Epilepsy, Altern. Med. Rev., 2007, 12(1), 9-24.
181. Gasch, A.T. Use of the traditional ketogenic diet for treatment of intractable epilepsy. J. Am. Diet. Assoc., 1990, 90, 1433-1434.
182. Acharya, M.M.; Hattiangady, B.; Shetty, A.K. Progress in neuroprotective strategies for preventing epilepsy. Prog. Neurobiol., 2008, 84, 363-404.
183. Gasior, M.; Rogawski, M.A.; Hartman, A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol., 2006, 17, 431-439.
184. Kim, D.Y.; Rho, J.M. The ketogenic diet and epilepsy. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11, 113-120.
185. Hartman, A.L.; Gasior, M.; Vining, E.P.; Rogawski, M.A. The neuropharmacology of the ketogenic diet. Pediatr. Neurol., 2007, 36, 281-292.
186. Bergqvist, A.G.; Brooks-Kayal, A.R. Ketogenic diet in the treatment of acquired epileptic aphasia. Ann. Neurol., 1997, 42, 505.
187. Czuczwar, S.J.; Ferenc, R.; Błaszczyk, B.; Borowicz, K.K. Neuroprotective effects of some newer and potential antiepileptic drugs. J. Pre-Clin. Clin. Res., 2007, 1(1), 1-5.
188. Pitkanen, A.; Kubova, H. Antiepileptic drugs in neuroprotection. Expert Opin. Pharmacother., 2004, 5(4), 777-798.
189. Stepien, K.; Tomaszewski, M.; Czuczwar, S.J. Profile of anticonvulsant activity and neuroprotective effects of novel and potential antiepileptic drugs-an update. Pharmacol. Rep., 2005, 57(6), 719-733.
190. Sullivan, P.G.; Readnower, R.D. In: Epilepsy; Rho, J.M.; Sankar, R.; Stafstrom, C.E. Ed.; CRC Press, Taylor & Francis Group: 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742, 2010; pp. 173-180.
191. Willmore, L.J. Antiepileptic drugs and neuroprotection: Current status and future roles. Epilepsy Behav., 2005, 7(Suppl 3), 25-28.
192. Rajasekaran, K. Seizure induced oxidative stress in rat brain regions: blockade by nNOS inhibition. Pharmacol. Biochem. Behav., 2005, 80, 263-272.
193. Sarnowska, A.; Beresewicz, M.; Zablocka, B.; Domanska-Janik, K. Diazepam neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABAAR and hypothermic effects. Neurochem Int., 2009, 55(1-3), 164-173.
194. Wallis, R.A., Panizzon, K.L. Felbamate neuroprotection against CA1 traumatic neuronal injury. Eur. J. Pharmacol., 1995, 294, 475-482.
195. Harty, T.P.; Rogawski, M.A. Felbamate block of recombinant Nmethyl-D-aspartate receptors: Selectivity for the NR2B subunit. Epilepsy Res., 2000, 39, 47-55.
196. White, H.S.; Wolf, H.H.; Swinyard, E.A.; Skeen, G.A.; Sofia, R.D. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia, 1992, 33, 564-572.
197. Pellock, J.M.; Perhach, J.L.; Sofia, R.D. In: Antiepileptic Drugs, Levy, R.H.; Mattson, R.H.; Meldrum, B.S.; Perucca, E., Ed.; Lippincott Williams & Wilkins: Philadelphia. 2002; 5th ed., pp. 301-318.
198. Gibbs, J.E.; Walker, M.C.; Cock, H.R. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia, 2006, 47(3), 469-478.
199. Wang, H.; Gao, J.; Lassiter, T.F.; McDonagh, D.L.; Sheng, H.; Warner, D.S.; Lynch, J.R.; Laskowitz, D.T. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit. Care, 2006, 5, 71-78.
200. Mariotti, V.; Melissari, E.; Amar, S.; Conte, A.; Belmaker, R.H.; Agam, G.; Pellegrini, S. Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays. Exp. Biol. Med., 2010, 235, 300-310.
201. Costa, C.; Martella, G.; Picconi, B.; Prosperetti, C.; Pisani, A.; Di Filippo, M.; Pisani, F.; Bernardi, G.; Calabresi, P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke, 2006, 37, 1319-1326.
202. Naziroglu, M.; Kutluhan, S.; Yilmaz, M. Selenium and topiramate modulates brain microsomal oxidative stress values, Ca2+ ATPase activity, and EEG records in pentylentetrazol induced seizures in rats. J. Membr. Biol., 2008, 225, 39-49.
203. Cui, J.; Shao, L.; Young, L.T.; Wang, J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neurosci., 2007, 144, 1447-1453.
204. Yis, U.; Seckin, E.; Kurul, S.H.; Kuralay, F.; Dirik, E. Effects of epilepsy and valproic acid on oxidant status in children with idiopathic epilepsy. Epilepsy Res., 2009, 84(2-3), 232-237.
205. Penas, C.; Verdu, E.; Asensio-Pinilla, E.; Guzman-Lenis, M.S.; Herrando-Grabulosa, M.; Navarro, X.; Casas, C. Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury. Neuroscience, 2011, 178, 33-44.
206. Marinova, Z.; Ren, M.; Wendland, J.R.; Leng, Y.; Liang, M.H.; Yasuda, S.; Leeds, P.; Chuang, D.M. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J. Neurochem., 2009, 111, 976-987.
207. Mori, A.; Noda, Y.; Packer, L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res., 1998, 30, 153-158.
208. Noda, Y.; Mori, A.; Packer, L. Zonisamide inhibits nitric oxide synthase activity induced by N-methl-D-aspartate and buthionine sulfoximine in the rat hippcampus. Res. Commun. Mol. Pathol. Pharmacol., 1999, 105, 23-33.
209. Waldbaum, S.; Patel, M. Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res., 2010, 88, 23-45.
210. Jain, K.K. An evaluation of zonisamide in the management of epilepsy. Expert Opin. Pharmacother., 2000, 1, 1245-1260.
211. Costa, C.; Tozzi, A.; Luchetti, E.; Siliquini, S.; Belcastro, V.; Tantucci, M.; Picconi, B.; Ientile, R.; Calabresi, P.; Pisani, F. Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Exp. Neurol., 2010, 221, 217-224.
212. Lowenstein, P.R.; Castro, M.G. Gene Therapy for Neurological Disorders, Taylor & Francis Group: New York, NY, 2006.
213. Boison, D.; Stewart, K.-A. Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem. Pharmacol., 2009, 78(12), 1428-1437.
214. Pitkanen, A.; Lukasiuk, K. Mechanisms of epileptogenesis and potential treatment targets, Neurology, 2011, 10, 173-186.
215. Palella, T.D.; Hidaka, Y.; Silverman, L.J.; Levine, M.; Glorioso, J.; Kelley, W.N. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene, 1989, 80, 137-144.
216. Noe, F.; Nissinen, J.; Pitkanen, A.; Gobbi, M.; Sperk, G.; During, M.; Vezzani, A. Gene therapy in epilepsy: the focus on NPY. Peptides, 2006, 28, 377-383.
217. McCown, T.J. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther., 2006, 14, 63-68.
218. Boison, D. Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. Neurodegener. Dis., 2007, 4, 28-33.
219. Riban, V.; Fitzsimons, H.L.; During, M.J. Gene therapy in epilepsy. Epilepsia, 2009, 50(1), 24-32.
220. Woldbye, D.P.D.; Angehagen, M.; Gotzsche, C.R.; Elbrond-Bek, H.; Sorensen, A.T.; Christiansen, S.H.; Olesen, M.V.; Nikitidou, L.; Hansen, T.V.O.; Kanter-Schlifke, I.; Kokaia, M. Adenoassociated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain, 2010, 133(9), 2778-2788.